HIL is betting that Nanoblaz’s nanotechnology could help them find cancer treatment
Non-invasive diagnostic test realizes the potential of circulating DNA for detection of multiple diseases
The novel technology was developed by Yinon Ben-Neriah, MD, PhD, Blumenthal Professor of Cancer Research, Lautenberg Center for Immunology, Hebrew University-Hadassah Medical School, with generous support by AMRF (The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation). Dr. Ben-Neriah and his team showed that inhibition of the clinically validated enzyme CKI-alpha induces several tumor suppressor pathways, including a new type of DNA damage response and p53 activation. This provides a novel approach to treat a wide range of cancers, in particular selective types of hematological malignancies.
Imagine nanoparticles that can carry a cancer drug directly to malignant cells and release it slowly for optimal effect.
Imagine a “green” method to transform plastic waste into valuable industrial products.
These inventions were among those highlighted at Innovations in Advanced Materials, a recent conference showcasing breakthrough nanotechnologies from Hebrew University of Jerusalem scientists for use in everything from sensors and coating materials to electronics and 3D printing.
Hebrew University's liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Yissum, the technology transfer company of the Hebrew University, has recently filed two provisional patent applications covering the promising Liver-on-Chip technology, that will be the basis of a new company to be established together with Prof. Yaakov Nahmias. This New Company will provide diagnostic and prognostic analysis for Pharmaceutical and Cosmetics companies to help define drug safety and screen out idiosyncratic drug toxicity.
Israeli researchers develop method to diagnose diabetes, multiple sclerosis, pancreatic cancer, pancreatitis and brain damage from one blood test.
"In the long run, we envision a new type of blood test aimed at the sensitive detection of tissue damage, even without [prior] suspicion of disease in a specific organ. We believe that such a tool will have broad utility in diagnostic medicine and in the study of human biology,” said Prof. Benjamin Glaser, head of endocrinology at Hadassah Medical Center and another lead author of the study along with Prof. Yuval Dor, a developmental biologist at the Hebrew University of Jerusalem."
Eight companies were founded in 2015 through Yissum based on research at the Hebrew University’s Center for Nanoscience and Nanotechnology.
Shades and curtains that can light up a room or darken a window, making them as transparent or as opaque as desired; monitoring of physiological parameters such as stress, fatigue, pain, alcohol influence, drug use, and other factors using electromagnetic emissions from sweat ducts; 3D printers that can print circuit boards and sensors; threads that are stronger than spider webs; and dozens of new nano-technology innovations and inventions.
It’s all part of the brave new world of nano-materials technology, in which nano-tech is employed to develop fibers, metals, and other materials to do the above and much more. In fact, all of those products and technologies were designed by Israeli high-tech firms Qlight, Neteera, Nano-Dimension, and Seevix, respectively.
What all those companies have in common is that they are graduates of technology developed at Hebrew University and promoted by Yissum, Hebrew U’s tech transfer company – and on March 29th, Yissum and Hebrew University will be sponsoring its first-ever Advanced Materials Conference.
JVP to Operate Jerusalem-based Startup Incubator for 8 Years in Partnership with Motorola Solutions, Reliance Industries and Yissum, the Research Development Company of the Hebrew University of Jerusalem
Scientists from The Hebrew University of Jerusalem, Columbia University Medical Center and The New York Stem Cell Foundation Research Institute have succeeded in generating a new type of embryonic stem cell that carries a single copy of the human genome, instead of the two copies typically found in normal stem cells.
Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today the formation of Neteera Technologies, developer of remote sensing technology of various human biological indicators. Neteera Technologies has completed its first round of funding, raising $2.0 million from private investors.
Melodea is pioneering the development of an economically viable industrial process for the extraction of Nano Crystalline Cellulose (known as NCC or CNC) from the sludge of the paper industry. It developes unique technologies to assemble the NCC into ecologically friendly foams as well as enhancement of strength and other properties of materials such as: bio-packaging, paper, acrylic glues and paints.
Exelon, for example, is a treatment for Alzheimer’s that helps patients cope with the disease and remain independent longer. Marketed by Novartis, the drug is based on research that was conducted at Hebrew University. Doxil, sold by Johnson and Johnson, effectively helps treat numerous cancers, and it, too, was developed at Hebrew U, along with researchers at Hadassah Medical Center. And, of course, there’s multiple sclerosis drug Copaxone, developed at the Weizmann Institute and marketed by Israel’s own Teva Pharmaceuticals.
Melodea develops environmentally-friendly, nano-crystalline cellulose based products from side streams of the paper industry
Using viruses from Jerusalem's sewage system, Hebrew University-Hadassah School of Dental Medicine researchers have developed an innovative treatment against dental bacteria that are resistant to growing numbers of antibiotics.
The team developed bacteriophage (“phages”) viruses to gobble up enterococcus bacteria that are resistant to a wide variety of antibiotics that is described by health authorities around the world as a major danger to health.
Capital to be used for completion of on-going Phase 2b study of ladostigil, for treatment of mild cognitive impairment, and preparations for pivotal Phase 3 trial
Eight start ups created in 2015 only!
New fiber optic guide-wire will enable surgeons to perform highly accurate hip fracture and spinal fusion surgery with minimal side effects
Troublemaking’ bacteria that is a major factor in periodontitis prevents the body from properly fending off cancerous cells, Hebrew U research shows
A saliva-based pregnancy test, a blood test to predict severe health issues, and a home printer which produces complex electronic equipment.
It sounds like science fiction, but for Israeli inventors and their clients, it is an achievable to-do list for the next two years.
Yaacov Michlin, chief executive of the Hebrew University's technology transfer arm Yissum, is responsible for helping researchers turn these innovative ideas into marketable products.
In terms of the outcomes Yissum can create from limited resources, Mr Michlin said the organisation was in the top five of its kind globally, and the largest and most active such company in Israel.